Comparison of spironolactone and spironolactone plus finasteride in the treatment of hirsutism

Fertility and Sterility

Volumn 78, Issue 6, 2002, Pages 1331-1333

  Ünlühizarci, Kürşad ^a   Everest, Hatice ^a   Bayram, Fahri ^a   Keleştimur, Fahrettin ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BOLDENONE; CYTOCHROME P450; FINASTERIDE; FLUTAMIDE; GONADORELIN DERIVATIVE; INSULIN; ORAL CONTRACEPTIVE AGENT; SPIRONOLACTONE; STEROID 5ALPHA REDUCTASE;

ANDROGEN BLOOD LEVEL; BLOOD CELL COUNT; BLOOD CHEMISTRY; BODY MASS; BREAKTHROUGH BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG COMPETITION; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HIRSUTISM; HUMAN; INSULIN SENSITIVITY; LETTER; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0036901694     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(02)04294-2     Document Type: Article

References (17)

1. Keleştimur F., Şahin Y. Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. Fertil Steril. 69:1998;66-69.
2. Şahin Y., Dilber S., Keleştimur F. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril. 75:2001;496-500.
3. Pittaway D.E., Maxson W.S., Wentz A.C. Spironolactone in combination drug therapy for unresponsive hirsutism. Fertil Steril. 43:1985;878-882.
4. Hatch R., Rosenfield R.L., Kim M.H., Tredway D. Hirsutism implications, etiology and management . Am J Obstet Gynecol. 140:1981;815-830.
5. Conn J.J., Jacobs H.S. The clinical management of hirsutism. Eur J Endocrinol. 136:1997;339-348.
6. AACE hyperandrogenism guidelines American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of hyperandrogenic disorders . Endocrine Practice. 7:2001;121-134.
7. Simard J., Luthy I., Guay J., Belanger A., Labrie F. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol. 44:1986;261-270.
8. Erenus M., Yücelten D., Durmuşoǧlu F., Gürbüz O. Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. Fertil Steril. 68:1997;1000-1003.
9. Shaw J.C. Spironolactone in dermatologic therapy. J Am Acad Dermatol. 24:1991;236-243.
10. Bayram F., Müderris I.I., Şahin Y., Keleştimur F. Finasteride treatment for one year in 35 hirsute patients. Exp Clin Endocrinol Diabetes. 107:1999;195-197.
11. Crosby P.D.A., Rittmaster R.S. Predictors of clinical response in hirsute women treated with spironolactone. Fertil Steril. 55:1991;1076-1081.
12. Wong I.L., Morris R.S., Chang L., Spahn M., Stanczyk F.Z., Lobo R. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab. 80:1995;223-238.
13. Castello R., Tosi F., Perrone F., Negri C., Muggeo M., Moghetti P. Outcome of long term treatment with the 5α-reductase inhibitor of finasteride in idiopathic hirsutism clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up . Fertil Steril. 66:1996;734-740.
14. McMullen G.R., Van Herle A.J. Hirsutism and the effectiveness of spironolactone in its management. J Endocrinol Invest. 16:1993;925-932.
15. Lobo R.A., Shoupe D., Serafini P., Brinton D., Horton R. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril. 43:1985;200-205.
16. Carmina E., Lobo R.A. Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism. Obstet Gynecol. 78:1991;845-849.
17. Schriock E.A., Schriock E.D. Treatment of hirsutism. Clin Obstet Gynecol. 34:1991;852-863.